Morgan Stanley Initiates Coverage On Avalyn Pharma with Overweight Rating, Announces Price Target of $53
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Morgan Stanley analyst Judah Frommer initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Overweight rating and announces Price Target of $53.
Morgan Stanley analyst Judah Frommer initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Overweight rating and announces Price Target of $53.